Actively Recruiting
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Led by Mabwell (Shanghai) Bioscience Co., Ltd. · Updated on 2026-03-12
280
Participants Needed
1
Research Sites
202 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.
CONDITIONS
Official Title
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Life expectancy of at least 3 months as assessed by the Investigator
- For Phase 1b: Histologically or cytologically confirmed locally advanced or metastatic solid tumor, progressive after last treatment or intolerant to approved therapies or lack of effective standard therapies
- For Phase 2: Histologically or cytologically confirmed locally advanced or metastatic selected advanced solid tumors
- Measurable or evaluable disease by RECIST v1.1
- Adequate hematopoietic, renal, and hepatic functions
- Men or women willing to use adequate contraceptive measures throughout the study
You will not qualify if you...
- Other prior malignancies within 3 years before first administration
- Known central nervous system metastatic disease or carcinomatous meningitis except for treated and stable brain metastases
- Significant, uncontrolled, or active cardiovascular disease
- History of COPD, intestinal lung disease, or other respiratory diseases requiring inpatient treatment within 4 weeks prior to first administration
- Adverse events from prior antitumor therapy not resolved to grade 1 or lower by NCI CTCAE V6.0
- Active infections requiring treatment within 14 weeks; infection of HIV, active HCV, or HBV
- Prior treatment with an antibody drug conjugate containing a topoisomerase I inhibitor
- Prior treatment with B7-H3 targeted agents
- Received any other investigational drugs or medical devices within 4 weeks prior to first administration
- Pregnant or nursing females
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200043
Actively Recruiting
Research Team
S
Shun Lu, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here